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L ung cancer is one of the most common forms of neoplasms and is the leading cause of cancer- 
related deaths in the world.  The treatment of choice in 
patients with Stage I,  Stage II and some subsets of Stage 
IIIA non-small cell lung cancer (NSCLC) is surgery.  
However,  the 5-year survival rate after a complete 
resection for all stages is approx.  60%,  and many 
patients develop recurrences [1].  To improve the out-
comes after resection,  adjuvant chemotherapy is rec-
ommended.  Platinum-based chemotherapy has become 
a standard regimen in patients with resected Stage II or 
IIIa disease,  and improvements in survival rates of 
2-15% have been reported [2-5].
In patients with advanced lung cancer or recurrence,  
many trials have evaluated new agents and/or treatment 
strategies to improve patient survival.  Some of these 
trials have examined maintenance therapy.  Mainte-
nance therapy is defined as a treatment that is per-
formed after the initial cycles of chemotherapy to main-
tain the response to the initial treatment for a longer 
period of time.  Patel et al.  reported that maintenance 
chemotherapy using bevacizumab after platinum-based 
chemotherapy demonstrated an improvement in overall 
survival in patients with advanced lung cancer [6].  
Other investigators have also reported that maintenance 
treatment using pemetrexed or gemcitabine improved 
the survival period [7 , 8].  Since then,  maintenance 
Acta Med.  Okayama,  2017
Vol.  71,  No.  6,  pp.  513-518
CopyrightⒸ 2017 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Feasibility Trial of Oral UFT after Platinum-based Adjuvant  
Chemotherapy in Patients with Resected Non-small Cell Lung Cancer
Shigeki Sawadaa＊,  Ryujiro Sugimotob,  Tsuyoshi Uenob,  and Motohiro Yamashitab
aDepartment of Thoracic Surgery,  Japanese Red Cross Society Himeji Hospital,  Himeji,  Hyogo 670-8540,  Japan,   
bDepartment of Thoracic Surgery,  National Hospital Organization Shikoku Cancer Center,  Matsuyama 791-0280,  Japan
We evaluated the feasibility of maintenance treatment using UFT (a combination of tegafur and uracil) after 
adjuvant platinum-based chemotherapy in patients with resected lung cancer.  A prospective feasibility trial was 
conducted.  Between 2010 and 2014,  UFT was administered for 2 years sequentially after platinum-based adju-
vant chemotherapy in 24 patients with resected Stage IIA-IIIA non-small cell lung cancer.  The safety of UFT 
and the rate of treatment completion were then evaluated.  The prior platinum-based chemotherapy regimens 
consisted of cisplatin + vinorelbine in 16 patients,  carboplatin + paclitaxel in 5 and carboplatin + S-1 in one.  
During the subsequent UFT administration,  a total of 3 patients required a dose reduction because of Grade 1 
blood-stained sputum,  Grade 2 numbness,  and Grade 2 constipation,  in one patient each.  Eleven patients 
underwent the planned 2-year UFT administration,  but 12 patients could not because of the recurrence of lung 
cancer in 5 patients,  metachronous malignancy in one,  and toxicities in 6.  The completion rate for UFT 
administration was 64.7% (11/17).  The most common type of toxicity was gastrointestinal toxicities.  All of the 
toxicities were grade 1 or 2,  and no severe toxicities were observed.  UFT treatment after platinum-based che-
motherapy was revealed to be feasible.
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treatment has become a treatment option for patients 
with advanced lung cancer or recurrence.  Based on the 
success of maintenance treatment in patients with 
advanced lung cancer,  maintenance treatment has also 
been applied as an adjuvant treatment in patients with 
complete resected NSCLC.  Niho et al.  reported the 
results of a feasibility trial using S-1 as a maintenance 
agent after the adjuvant administration of three cycles of 
cisplatin and docetaxel.  They reported that the 
6-month completion rate for maintenance treatment 
using S-1 after three cycles of cisplatin and docetaxel 
was 51.2%,  and they did not meet their criterion for 
feasibility,  although the toxicity of S-1 was acceptable.  
They concluded that modification of the S-1 treatment 
schedule might be necessary to improve compliance [9].
UFT is an oral anticancer agent that is a combina-
tion of tegafur and uracil in a molar ratio of 1 : 4.  
Although UFT is in the same category of anticancer 
agents as S-1,  it is thought to have a milder adverse 
effect profile.  We therefore considered that UFT might 
be a more suitable agent for maintenance treatment 
after platinum-based chemotherapy,  and we conducted 
the following feasibility trial of maintenance treatment 
using UFT after adjuvant platinum-based chemother-
apy in patients with resected lung cancer.
Patients and Methods
A prospective feasibility trial was conducted.  This 
study was approved by our Institutional Review Boards 
No. 2016-130 and was conducted in compliance with 
the guidelines of good clinical practice and the princi-
ples of the Declaration of Helsinki.  All of the patients 
provided written informed consent prior to study entry.  
The study was registered in the UMIN Clinical Trials 
Registry as UMIN000003204.  Enrollment began in 
2010 and closed in August 2014 (Fig. 1).
The criteria for patient eligibility were as follows:  
patients who underwent at least one cycle of plati-
num-based chemotherapy for completely resected Stage 
II-IIIA NSCLC,  age > 20 years,  and an Eastern Coop-
erative Oncology Group (ECOG) performance status 
(PS) of 0 or 1.  Other criteria included a PaO2 at room 
air ≥ 70 torr or an SpO2 at room air ≥ 95% and adequate 
organ function (i.e.,  total bilirubin ≤ 1.5 mg/dL,  AST 
and ALT ≤ 100 IU/L,  leukocyte count ≥ 2,000 and 
≤ 12,000/mm3,  neutrophil count ≥ 1,000/mm3,  hemo-
globin ≥ 10.0 g dl/L,  and platelets ≥ 75,000/mm3).  
Patients were required to start the protocol UFT admin-
istration within 8 weeks after the prior platinum-based 
adjuvant chemotherapy.  The key exclusion criteria were 
active infection; interstitial pneumonia as determined 
using CT of the chest; severe diarrhea; active concom-
itant malignancy; pregnancy or breast-feeding; and a 
history of hypersensitivity to UFT.  Disease staging was 
performed according to the Union International Cancer 
Control (UICC) 7th TNM edition [10].
Administration of UFT. Daily oral UFT was ini-
tiated within 8 weeks after the prior adjuvant plati-
num-based chemotherapy,  and this treatment was 
planned to continue for 2 years.  The dose of UFT was 
selected according to each patient’s body surface area 
(BSA) as follows: those with a BSA of ≤ 1.39 m2 
received 300 mg/day; those with a BSA of ≥ 1.40 m2 
but ≤ 1.79 m2 received 400 mg/day; and those with a 
BSA of ≥ 1.80 m2 received 500 mg/day.  In the event of 
Grade 3 hematologic toxicity or Grade 2 non-hemato-
logic toxicity,  the administration of UFT was stopped 
until these factors recovered to the inclusion criteria 
levels and then was restarted at a one-rank lower dose.  
In the cases with an initial dose of 300 mg/day,  treat-
ment at a dose of 300 mg was resumed and the protocol 
was terminated if the toxicity reappeared.
Safety assessment and follow-up. A follow-up 
evaluation was performed every 3 months for the first 2 
years and every 6 months thereafter.  The evaluation 
included a physical examination,  a complete blood 
count,  blood chemical tests,  screening for serum tumor 
markers,  and chest radiography.  A CT scan of the tho-
rax and the upper abdomen were obtained every 6 
months for the first 2 years after the operation and 
annually for the subsequent 3 years.  Toxicities were 
graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE),  version 3.0.
Statistical analysis. The primary endpoint was 
feasibility,  which was defined as the proportion of 
patients who completed the 2-year UFT administration 
period; secondary endpoints were recurrence-free sur-
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Fig. 1　 Study protocol.
vival,  overall survival,  and safety.  The sample size was 
calculated based on the following assumptions: a 2-year 
UFT treatment completion rate of 50%,  with a rate of 
30% being the lower limit of interest,  and α = 0.05 and 
1−β=0.8; the estimated accrual number was 47 patients.  
The study was started in January 2010 but was termi-
nated with 23 patients in August 2014 because of slow 
accrual.
Results
Patient background. Twenty-three patients were 
enrolled in UFT maintenance treatment after platinum- 
based chemotherapy.  The characteristics of these 23 
patients (17 males,  6 females) are listed in Table 1.  The 
median age was 64 years (range 36-81 years).  Histological 
examination revealed adenocarcinoma in 14 patients,  
squamous cell carcinoma in 6 patients,  and others in 3 
patients; the p-stage was p-Stage IIA in 12 patients,  IIB 
in 2 and IIIA in 9.  A segmentectomy was performed in 
1 patient,  a lobectomy was performed in 20 patients,  
and more extended resection was performed in 2 
patients.
The prior platinum-based chemotherapy regimen 
was CDDP + VNR in 16 patients,  CBDCA + PTX in 5 
and CBDCA + S-1 in 1.  Fourteen patients completed 
four cycles of chemotherapy,  but the remaining nine 
patients did not.
UFT administration. After the platinum-based 
chemotherapies,  the administration of UFT was initi-
ated.  Three patients required a dose reduction: Grade 
1 blood-stained sputum,  Grade 2 numbness,  and Grade 
2 constipation,  in 1 patient each.  Eleven patients com-
pleted the planned 2-year UFT administration,  but the 
other 12 patients did not (Table 2).  The reasons for the 
termination of UFT administration were the recurrence 
of lung cancer in 5 patients,  a metachronous malig-
nancy in 1,  and toxicities in 6.  The 6 patients who 
developed recurrences and metachronous malignancy 
were excluded from the calculation of the UFT comple-
tion rate,  which was calculated to be 64.7% (11/17).
The toxicity profile for UFT is shown in Table 3.  The 
most common type of toxicities was gastrointestinal 
toxicities.  All of the toxicities were grade 1 or 2,  and no 
severe toxicities were observed (Table 3).
Of the 14 patients who underwent 4 cycles of prior 
platinum-based chemotherapy,  8 patients completed 
the 2-year UFT administration,  three patients discon-
tinued UFT administration because of recurrence or 
metachronous malignancy,  and 3 patients discontinued 
UFT treatment because of adverse effects.  Of the 9 
patients who did not undergo 4 cycles of prior chemo-
therapy,  3 patients completed the 2-year UFT adminis-
tration,  3 patients discontinued UFT administration 
because of recurrence or metachronous malignancy,  
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Table 1　 Patient characteristics
Age,  years,  median (range) 64 (36 -81)
Male/Female 17/6
Stage
　　　　　　　　IIA/IIB/IIIA 12/2/9
Histological subtype
　　　　　　　　Adeno/Sq/Others 14/6/3
Extent of resection
　　　　　　　　Segmentectomy 1
　　　　　　　　Lobectomy 20
　　　　　　　　More extended resection 2
Prior chemo regimen
　　　　　　　　CDDP＋VNR 16
　　　　　　　　CBDCA＋PTX 5
　　　　　　　　CBDCA＋S-1 2
Cycles of prior chemotherapy
　　　　　　　　4 14
　　　　　　　　3 1
　　　　　　　　2 3
　　　　　　　　1 5
Adeno,  adenocarcinoma; CBDCA,  carboplatin; CDDP,  cisplatin;  
PTX,  paclitaxel; Sq,  squamous cell carcinoma; VNR,  vinorelbine.
Table 2　 Administration of UFT
Duration of UFT administration (median,  range) 14 (1-25)
2-year completion 11
1-2 years 2
0.5-1 year 3
＜0.5 years 7
Table 3　 Toxicity of UFT
G1 G2 ≥G3
Nausea 1 1 0
Vomiting 1 0 0
Dysgeusia 1 0 0
Blood-stained sputum 1 0 0
Pneumonia 1 0 0
Constipation 1 0 0
Numbness 1 0 0
and 3 patients discontinued UFT treatment because of 
adverse effects (Table 4).
The median follow-up period was 48.5 months after 
registration.  The 5-year recurrence-free survival rate 
was 69.3%,  and the 5-year overall survival rate was 
66.7%.
Discussion
Several studies have evaluated the efficacy of adju-
vant treatment with UFT against lung cancer and other 
types of solid tumors [11 , 12].  Wada et al.  conducted a 
phase III trial and evaluated the efficacy of adjuvant 
UFT in patients with resected Stage I,  II,  or III lung 
cancer [13].  In their study,  the patients were random-
ized into 3 groups: CDDP + VDS followed by 1-year 
UFT,  1-year UFT,  and observation alone.  The survival 
period was evaluated.  The 5-year survival rates were 
60.6% in the CDDP + VDS followed by 1-year UFT 
group,  64.1% in the 1-year UFT group,  and 49.0% in 
the observation-alone group.  These results demon-
strated the efficacy of UFT in the setting of adjuvant 
treatment.  Wada et al.  included a regimen of CDDP +  
VDS followed by 1-year UFT in their study,  although 
their administration period of UFT was 1 year and was 
different from our study.  It is interesting and surprising 
that they conducted and included the CDDP + VDS 
regimen during a period when the concept of mainte-
nance treatment was not common,  although they did 
not refer to it as a maintenance treatment.
Kato et al.  also reported a survival benefit of UFT 
administered as an adjuvant chemotherapy in patients 
with resected Stage I lung cancer [14].  Since then,  
adjuvant treatment using UFT has become a standard 
treatment option in Japan for patients with resected 
Stage I disease,  especially those with T2a Stage IB dis-
ease.  Platinum-based chemotherapy is recommended 
for patients with resected Stage II or IIIA diseases.  In 
the present study,  UFT was used as a maintenance 
agent after platinum-based chemotherapy in patients 
with resected Stage II or IIIA disease under the expecta-
tion that it would exert an additional effect.
A unique point of the present study was that it 
included patients who could not complete 4 cycles of 
platinum-based chemotherapy.  The completion rate for 
4 cycles of platinum-based adjuvant chemotherapy was 
reported to be 50-80%,  and approximately one-third of 
the patients could not complete all 4 cycles of chemo-
therapy because of toxicities [4 , 5 , 15].  Ramsden et al.  
reported that a smaller dose of platinum-based chemo-
therapy was associated with a poorer survival outcome 
[16].  This indicated that patients who could not com-
plete 4 cycles of chemotherapy might receive a smaller 
benefit than those who could.  One of the purposes of 
the present study was to salvage those patients who 
could not undergo 4 cycles of chemotherapy and to 
improve their outcomes using UFT after incomplete 
platinum-based chemotherapy.
In this study,  the nine patients who could not com-
plete 4 cycles of chemotherapy underwent UFT admin-
istration.  Of them,  three patients discontinued UFT 
treatment because of toxicities,  but the remaining 6 
patients were able to undergo the administration of UFT 
for the planned 2 years or until recurrence.  UFT 
administration was considered to be well tolerated in 
the patients who could not undergo 4 cycles of plati-
num-based chemotherapy.  UFT was also administered 
to the 14 patients who completed 4 cycles of plati-
num-based chemotherapy.  The completion rate for the 
2-year UFT administration was 73%.  Thus,  UFT after 
platinum-based chemotherapy is considered to be feasi-
ble in both patients who are able to complete 4 cycles of 
platinum-based chemotherapy and those who cannot.
Niho et al.  reported a similar feasibility trial using 
S-1 as a maintenance agent.  They included 129 patients 
and administered 3 cycles of DOC + CDDP and then 
administered S-1; 106 patients completed the 3 cycles 
of DOC+ CDDP.  Of them,  66 patients (66/106= 66.2%) 
underwent the UFT regimen for ≥ 6 months.  In our 
present study,  16 patients (16/23 = 70.0%) were able to 
undergo the UFT regimen for ≥ 6 months.  It is difficult 
to compare the results reported by Niho et al.  with our 
results because the treatment protocols were different,  
but the compliance to S-1 and UFT appears to be com-
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Table 4　 Compliance with UFT treatment according to the num-
ber of cycles of prior chemotherapy
4 cycles of prior chemotherapy 14
Completion of 2-year administration 8
Discontinuation because of adverse eﬀect 4
Discontinuation because of recurrence or second malignancy 3
1-3 cycles of prior chemotherapy 9
Completion of 2-year administration 3
Discontinuation because of adverse eﬀect 3
Discontinuation because of recurrence or second malignancy 3
patible.
In this study,  the completion rate for the 2-year 
UFT treatment was calculated as 64.7% (11/17).  We 
excluded 6 patients who developed recurrences from 
this calculation.  From an intent-to-treat standpoint,  
however,  the completion rate should have been calcu-
lated using all 23 patients.  In cases of platinum-based 
chemotherapy,  the duration of treatment is approx.  2 
or 3 months.  The development of recurrences during 
this short period is relatively rare,  and the number of 
cases requiring the discontinuation of chemotherapy 
because of recurrence can be ignored.  On the other 
hand,  the planned duration of UFT administration was 
as long as 2 years in this study.  Six patients developed 
recurrences during the UFT treatment period and dis-
continued UFT treatment.  The frequency of UFT dis-
continuation because of recurrence cannot be ignored,  
but we failed to consider this aspect when writing the 
protocol for this study.  However,  since the purpose of 
this study was to evaluate the feasibility and safety of 
UFT,  we decided that it was reasonable to remove the 6 
patients from the analysis of the completion rate.
Grade 1 adverse effects were observed in 3 patients,  
and a Grade 2 adverse effect was observed in 1 patient;  
Grade 3 or 4 adverse effects were not observed.  None of 
the adverse effects were serious,  and the UFT adminis-
tration can be considered to have been tolerable; nev-
ertheless,  seven patients discontinued the treatment.  
Kato et al.  also reported that the completion rate of the 
2-year administration of UFT was as low as 61%,  
although the adverse effects were not serious.  Although 
platinum-based chemotherapy is relatively toxic,  pre-
ventative treatments and management strategies have 
been improved.  Moreover,  the treatment duration is 
limited to 3 months,  and patients manage to endure 
four cycles of chemotherapy.  In contrast,  the treatment 
period of UFT was as long as 2 years.  Although the 
adverse effects were not serious and were considered 
tolerable,  longer treatment periods can be overwhelm-
ing,  leading to the discontinuation of UFT treatment.
Another factor associated with the low compliance 
with UFT treatment might be a doctor-related factor.  
The patients enrolled in this study had already under-
gone standard platinum-based chemotherapy,  and the 
physicians in charge of the patients’ care might have 
decided to discontinue the UFT treatment relatively 
easily.
One of issues of this study is statistical reliability.  
The study size was designed to be 47 patients,  but the 
study was stopped after the enrollment of 23 patients 
because of the slow accrual,  and there is thus a concern 
about the statistical power to evaluate the primary end 
point.  The completion rate was 64.7%,  which is above 
the value of the primary end point of 50%.  Although 
there is the concern about statistical power,  the primary 
end point seems to have been accomplished,  and the 
administration of UFT after platinum-based chemo-
therapy was considered feasible.  The survival benefit 
delivered by UFT maintenance treatment was not 
determined in this study,  since the number of the 
patients was too small to evaluate it.  The utility of UFT 
maintenance after platinum-based chemotherapy 
should be confirmed in a large phase III trial.
In conclusion,  UFT administration after platinum- 
based chemotherapy in patients with resected lung can-
cer was evaluated.  The completion rate of the 2-year 
UFT administration was 64.7%,  and no severe adverse 
effects were encountered.  Thus,  UFT maintenance 
treatment is considered to be feasible in this patient 
population.
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